BTK and mantle cell lymphoma: Conversely, for the two patients with less acalabrutinib-sensitive disease (MCL#0528 and MCL#0533), the mass distributions of MCL cells pre- and on-treatment appear to have a similar profile, suggesting that BTK inhibition did not consequentially alter the biophysical properties of these MCL cells.